(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.30%) $79.19
(0.00%) $2.04
(0.11%) $2 312.10
(0.23%) $26.89
(0.08%) $963.40
(-0.02%) $0.932
(-0.04%) $10.99
(-0.06%) $0.797
(-0.01%) $91.12
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 9.67%
Live Chart Being Loaded With Signals
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally...
Stats | |
---|---|
今日成交量 | 4.52M |
平均成交量 | 2.34M |
市值 | 4.98B |
EPS | $0 ( 2024-02-15 ) |
下一个收益日期 | ( $0.930 ) 2024-06-04 |
Last Dividend | $0.280 ( 2023-11-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | 4.89 |
ATR14 | $0.0370 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-29 | Arjona Ferreira Juan Camilo | Buy | 108 932 | Stock Option (right to buy) |
2024-03-29 | Arjona Ferreira Juan Camilo | Buy | 26 595 | Restricted Stock Units |
2024-03-31 | Morrissey Joseph T. Jr. | Buy | 7 794 | Common Stock |
2024-03-31 | Morrissey Joseph T. Jr. | Sell | 2 328 | Common Stock |
2024-03-31 | Morrissey Joseph T. Jr. | Buy | 3 936 | Common Stock |
INSIDER POWER |
---|
64.91 |
Last 100 transactions |
Buy: 2 246 661 | Sell: 486 702 |
音量 相关性
Organon & Co. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Organon & Co. 相关性 - 货币/商品
Organon & Co. 财务报表
Annual | 2023 |
营收: | $6.26B |
毛利润: | $3.75B (59.84 %) |
EPS: | $4.01 |
FY | 2023 |
营收: | $6.26B |
毛利润: | $3.75B (59.84 %) |
EPS: | $4.01 |
FY | 2022 |
营收: | $6.17B |
毛利润: | $3.88B (62.84 %) |
EPS: | $3.61 |
FY | 2021 |
营收: | $6.30B |
毛利润: | $3.92B (62.21 %) |
EPS: | $5.33 |
Financial Reports:
No articles found.
Organon & Co. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.280 | 2021-08-20 |
Last Dividend | $0.280 | 2023-11-10 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-14 | |
Next Payout Date | N/A | |
# dividends | 10 | -- |
Total Paid Out | $2.80 | -- |
Avg. Dividend % Per Year | 2.08% | -- |
Score | 4.27 | -- |
Div. Sustainability Score | 7.83 | |
Div.Growth Potential Score | 4.39 | |
Div. Directional Score | 6.11 | -- |
Year | Amount | Yield |
---|---|---|
2021 | $0.560 | 1.68% |
2022 | $1.120 | 3.59% |
2023 | $1.120 | 3.99% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.163 | 1.500 | 6.73 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0848 | 1.200 | 7.17 | 8.61 | [0 - 0.3] |
returnOnEquityTTM | -2.10 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0.287 | -1.000 | 7.13 | -7.13 | [0 - 1] |
currentRatioTTM | 1.545 | 0.800 | 7.28 | 5.82 | [1 - 3] |
quickRatioTTM | 0.835 | 0.800 | 9.79 | 7.83 | [0.8 - 2.5] |
cashRatioTTM | 0.237 | 1.500 | 9.79 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.726 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 1.221 | 1.000 | -0.659 | -0.659 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.13 | 2.00 | 8.96 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.10 | 2.00 | 8.95 | 10.00 | [0 - 20] |
debtEquityRatioTTM | -125.14 | -1.500 | -10.00 | 10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.598 | 1.000 | 3.36 | 3.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.103 | 1.000 | 9.94 | 9.94 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0912 | 1.000 | -0.604 | -0.604 | [0.2 - 2] |
assetTurnoverTTM | 0.519 | 0.800 | 9.87 | 7.90 | [0.5 - 2] |
Total Score | 7.83 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 4.71 | 1.000 | 9.63 | 0 | [1 - 100] |
returnOnEquityTTM | -2.10 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.10 | 2.00 | 9.30 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 5.95 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.13 | 2.00 | 8.96 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.287 | 1.500 | 7.13 | -7.13 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.128 | 1.000 | 9.31 | 0 | [0.1 - 0.5] |
Total Score | 4.39 |
Organon & Co.
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。